Search Videos and More
News
Dana-Farber/Boston Children's Named the Top Pediatric Cancer Program in the Nation for 2026-2027
U.S. News & World Report has recognized Dana-Farber/Boston Children’s Cancer and Blood Disorders Center as the #1 pediatric cancer program in the nation in its 2026-2027 Best Children’s Hospitals report.
News
Dana-Farber Research News 09.15.2026
This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from August 16 - 31.
News
Targeting CDK2 Could Boost Immunotherapy Response in Patients With a Wide Range of Cancers, According to Dana-Farber Science
New research from Dana-Farber Cancer Institute scientists suggests that cyclin-dependent kinase 2 (CDK2) inhibitors, which are currently being tested as treatments that slow the growth of a narrow range of cancers, could potentially be more broadly applicable to a wide range of cancers when combined with immunotherapy.
News
Dana-Farber Research News 09.01.2026
This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from August 1 - 15.
News
FDA Approves Daraxonrasib for Metastatic Pancreatic Cancer Following Landmark Clinical Trial Led by Dana-Farber
he U.S. Food and Drug Administration (FDA) has approved daraxonrasib, an oral multi-selective RAS(ON) inhibitor, for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy.
Course
Stem Cell Transplant and Cellular Therapies Symposium 2026:
Navigating a Rapidly Changing Landscape
News
Dana-Farber Research News 08.15.2026
This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from July 16 - 31.
News
FDA Approves First CELMoD Agent, with Dana-Farber Helping Advance its Development
The U.S. Food and Drug Administration has approved iberdomide in combination with daratumumab and dexamethasone for patients with relapsed or refractory multiple myeloma, making it the first approved cereblon E3 ligase modulator (CELMoD) for this disease.
News
Dana-Farber Investigators Develop Protein Degrader Discovery Platform and Find First-in-Kind Metabolically Activated Molecular Glue Degrader
Investigators at Dana-Farber Cancer Institute have developed a platform for systematically discovering molecular glues that could become protein degradation drug candidates. The platform could help drug developers dramatically expand the range of disease-related proteins that can be therapeutically targeted for elimination via protein degradation.
News
Collaborative Team Doubles Number of In Vitro Patient-Derived Cancer Models Available for Research
A collaborative team led by investigators from Dana-Farber Cancer Institute and elsewhere developed 665 next-generation patient-derived cancer models across 27 common and rare forms of cancer and made the models plus relevant clinical and molecular data available as a resource to researchers around the globe to accelerate cancer advances.
News
U.S. News & World Report Names Dana-Farber Brigham Cancer Center #1 Locally, #3 Nationally for 2026-2027
Dana-Farber Brigham Cancer Center has been recognized as the Best Hospital for Cancer in Massachusetts and ranked #3 in the nation by U.S. News & World Report. This is the 26th consecutive year Dana-Farber Brigham has been recognized for its excellence in caring for people with cancer.
News
Dana-Farber Research News 08.01.2026
This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from July 1 - 15.